Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy

CD79B wide-type and not achieving CR during interim responses evaluation correlate with POD12. These findings provide a basis for the development of optimal alternative therapies in clinical trials.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-02-18
DOI
https://doi.org/10.3389/fonc.2026.1682952
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy

Yong Su, Liu Shi, Xiaohua Liu, Di Deng et al.
Frontiers in Oncology
Lymphoma Diagnosis and Treatment
article

Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy

Yong Su, Liu Shi, Xiaohua Liu, Di Deng, Jing Wang
article en

Abstract

CD79B wide-type and not achieving CR during interim responses evaluation correlate with POD12. These findings provide a basis for the development of optimal alternative therapies in clinical trials.

Frontiers in OncologyVol. 16
Wuhan University (CN), Jiangxi Provincial Cancer Hospital (CN), Zhongnan Hospital of Wuhan University (CN)
No poverty
Openalex Percentile: Top 52%
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.